SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
MRI or magnetic resonance imaging of the head and brain. Close up
Insights
The New Gold Rush in Brain Science
Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, even amid costly setbacks. BioSpace spoke to investors at JPM26 to get their take on recent bets in new therapies and neurotech.
January 22, 2026
 · 
5 min read
 · 
Jennifer Smith-Parker
Illustration showing paper people silhouettes collage with newspaper text cutouts
Job Trends
Increasingly Competitive Job Market Worries, Frustrates Biopharma Professionals
Competition for biotech and pharma employment picked up year over year and remains strong, according to BioSpace data. A survey late last year showed that 64% of employed/contract and 96% of unemployed respondents will actively look for work in 2026.
January 22, 2026
 · 
5 min read
 · 
Angela Gabriel
Johnson and Johnson sign
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
January 21, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
The Biotech CEO Sisterhood gathered women leaders and allies in Union Square during the J.P. Morgan Healthcare Conference on January 13, 2026.
C-suite
JPM26: Filling C-Suites, Union Square—and Elevators—With Pink
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
January 21, 2026
 · 
2 min read
 · 
Annalee Armstrong
Industry Leader and Market Dominance of a Company
Business
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
January 21, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Facade of Novo Nordisk's office in Fremont, California
Cell therapy
After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact
Novo Nordisk pulled back from cell therapies last October, scrapping development of a type 1 diabetes therapy and laying off most employees working on this modality.
January 21, 2026
 · 
2 min read
 · 
Tristan Manalac
Dec 3, 2019 South San Francisco / CA / USA - Genentech headquarters in San Francisco Bay Area; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009
Manufacturing
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.
January 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Reaching an agreement. Businessmen shake hands and make a deal. vector
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Ahead of GSK are Bristol Myers Squibb and Merck, which have already won FDA approvals for subcutaneous formulations of their respective PD-1 blockers Opdivo and Keytruda.
January 21, 2026
 · 
1 min read
 · 
Tristan Manalac
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS